Prostate cancers have also been shown to secrete factors such as transforming growth factor beta (TGFβ), interleukin-10 (IL-10), and vascular endothelial growth Factor (VEGF) [53,54], constructing an immunosuppressive milieu that may demonstrate resistance to immunotherapy. This evidence concerns the gene TGFB1 and prostate carcinoma.